These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15324517

  • 1. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S59-66. PubMed ID: 15324517
    [Abstract] [Full Text] [Related]

  • 2. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [Abstract] [Full Text] [Related]

  • 3. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 5. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S, Valentine WJ, Evers T, Palmer AJ.
    Curr Med Res Opin; 2006 Jul; 22(7):1415-24. PubMed ID: 16834840
    [Abstract] [Full Text] [Related]

  • 6. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [Abstract] [Full Text] [Related]

  • 7. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S53-8. PubMed ID: 15324516
    [Abstract] [Full Text] [Related]

  • 8. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Aug; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 9. Validation of the CORE Diabetes Model against epidemiological and clinical studies.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S27-40. PubMed ID: 15324514
    [Abstract] [Full Text] [Related]

  • 10. Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis.
    Smith-Palmer J, Curtis BH, Boye KS, Goodall G, Pillemer SR.
    Diabet Med; 2010 Feb; 27(2):189-96. PubMed ID: 20546263
    [Abstract] [Full Text] [Related]

  • 11. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
    Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S41-51. PubMed ID: 15324515
    [Abstract] [Full Text] [Related]

  • 12. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA.
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [Abstract] [Full Text] [Related]

  • 13. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C, PROactive Study Group.
    Value Health; 2009 Apr; 12(1):1-9. PubMed ID: 18657104
    [Abstract] [Full Text] [Related]

  • 14. The importance of beta-cell management in type 2 diabetes.
    Standl E.
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [Abstract] [Full Text] [Related]

  • 15. A disease management programme for patients with diabetes mellitus is associated with improved quality of care within existing budgets.
    Steuten LM, Vrijhoef HJ, Landewé-Cleuren S, Schaper N, Van Merode GG, Spreeuwenberg C.
    Diabet Med; 2007 Oct; 24(10):1112-20. PubMed ID: 17672862
    [Abstract] [Full Text] [Related]

  • 16. Using an economic model of diabetes to evaluate prevention and care strategies in Australia.
    Colagiuri S, Walker AE.
    Health Aff (Millwood); 2008 Oct; 27(1):256-68. PubMed ID: 18180502
    [Abstract] [Full Text] [Related]

  • 17. Lifetime health effects and costs of diabetes treatment.
    Niessen LW, Dijkstra R, Hutubessy R, Rutten GE, Casparie AF.
    Neth J Med; 2003 Nov; 61(11):355-64. PubMed ID: 14768718
    [Abstract] [Full Text] [Related]

  • 18. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 19. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.
    Rev Invest Clin; 2005 Aug; 57(3):399-405. PubMed ID: 16187699
    [Abstract] [Full Text] [Related]

  • 20. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.
    Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S.
    Int J Clin Pract; 2006 Sep; 60(9):1138-45. PubMed ID: 16939559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.